Events

Poster Presentation: AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma as a Single Agent and in Combination With Approved Therapeutics

Poster Presentation: Pre-clinical Combination of AO-176, a Highly Differentiated Clinical Stage CD47 Antibody, with Either Azacitidine or Venetoclax Significantly Enhances DAMP Induction and Phagocytosis of Acute Myeloid Leukemia

Poster Presentation: Highly Differentiated Anti-CD47 Antibody AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination in Pre-Clinical Models

Poster Presentation: Novel SIRP Antibodies with Differentiated Characteristics for Targeting Innate Immunity in Cancer

Poster Presentation: AO-176, a highly differentiated humanized anti-CD47 antibody, exhibits single-agent and combination anti-tumor efficacy with chemotherapy and targeted antibodies in preclinical models (Abstract #: B100)

Poster Presentation:  AO-176, a normal cell sparing humanized anti-CD47 antibody

Poster Presentation: Evaluation of novel anti-SIRP antibodies as potential cancer therapeutics

Poster Presentation: Therapeutic potential of AO-176, a next-generation humanized CD47 antibody, for hematologic malignancies

Poster Presentation: Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anti-cancer properties and negligible binding to red blood cells

Poster Presentation: AO-176, next-generation CD47 antibody, induces immunogenic cell death